Related Experiment Videos

The role of glycoprotein IIb/IIIa-receptor antagonists in diabetics

Kurt Huber1

  • 13rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria. kurt.huber@wienkav.at

Journal of Thrombosis and Thrombolysis
|November 18, 2003
PubMed

Insights

Glycoprotein IIb/IIIa receptor inhibitors are effective antithrombotics for high-risk patients, especially diabetics undergoing procedures. More prospective trials are needed to confirm benefits in diabetic populations.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitors are established antithrombotic agents.
  • Diabetic patients represent a high-risk group potentially benefiting from GP IIb/IIIa inhibitors.
  • Abciximab has the most data among GP IIb/IIIa inhibitors in diabetic patients.

Purpose of the Study:

  • To review the effectiveness of GP IIb/IIIa inhibitors in diabetic patients.
  • To highlight the need for further prospective research in this specific patient group.

Main Methods:

  • Review of existing retrospective subgroup analyses and meta-analyses.
  • Focus on data concerning GP IIb/IIIa inhibitors in diabetic patients undergoing percutaneous coronary interventions or with unstable angina/non ST-elevation myocardial infarction.

Main Results:

  • GP IIb/IIIa inhibitors demonstrate effectiveness in diabetic patients, supported by retrospective data.
  • Abciximab shows consistent data in diabetic populations compared to other agents.

Conclusions:

  • GP IIb/IIIa inhibitors are effective antithrombotics in high-risk diabetic patients.
  • Prospective trials with well-defined diabetic patient groups are essential to solidify these findings.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...